<div id="readability-page-1"><div><p>Indian pharmaceutical companies over the past year have ramped up manufacturing capabilities in anticipation of March 20, when the patent on semaglutide, the molecule behind Danish pharma major Novo Nordisk’s blockbuster weight-loss drugs Ozempic and Wegovy, expired. Building on India’s capabilities as a producer of cost-effective generic drugs, domestically produced generic injectable and oral formulations of semaglutide are expected to hit the market soon. Generics from drug majors Cipla, Sun Pharma, Dr Reddy’s Laboratories, Biocon, Natco, Zydus, and Mankind Pharma could cause these drug prices to plummet 50-70 per cent. Novo Nordisk’s patents in Europe and the United States (US), India’s biggest export markets for generics, will expire only in 2031, implying intense competition in the domestic market until then. This alone offers substantial gains for branded generics, given India’s deteriorating health parameters. According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight. This apart, some 77 million Indians suffer from Type 2 diabetes. Both are considered “lifestyle” diseases, the product of carb- and oil-heavy diets and inadequate exercise. Both diseases offer domestic manufacturers of generics large addressable markets. The market has already grown rapidly — from $16 million in 2021 to $100 million in 2025. It is expected to grow eightfold by 2030.</p></div></div>

诺德股份

诺和诺德公司

<p>印度制药公司正在准备推出赛马鲁肽的仿制药版本，因诺和诺德的专利已到期。像 Cipla 和 Sun Pharma 这样的主要公司预计将价格降低 50-70%。随着印度肥胖和糖尿病发病率的上升，这些药物的市场预计将显著增长，从 2021 年的 1600 万美元增长到 2025 年的 1 亿美元。然而，关于药物质量和安全性的担忧依然存在，尤其是考虑到过去的丑闻和假冒药物的风险。有效使用这些减肥药物需要适当的医疗监督</p>

有效的监管：安全性是减肥药物成功的关键